Table 1.

Funding for malaria research in sub-Saharan Africa for 1997–2013 by product area and type of science

		Number of awards	Proportion of total awards (%)	Total investment (US$)	Proportion of total investment (%)	Mean award size (US$)*	Median award size (US$)†
Product area
	Diagnostics	29	9%	41 010 386	5·0%	14 14 151 (1 670 125)	906 950 (409 574–1 430 935)
	Vaccines	18	5%	64 995 864	8·0%	3 610 881 (3 394 021)	2 909 619 (510 504–4 855 510)
	Therapeutics	83	25%	261 205 837	32·1%	3 147 058 (5 731 588)	991 048 (326 333–3 910 552)
Type of science
	Phase 1–3 clinical trials	80	24%	275 214 430	33·8%	3 440 180 (4 787 761)	1 317 954 (426 077–4 955 076)
	Intervention and product development	35	11%	87 580 346	10·8%	2 502 296 (4 186 004)	999 485 (293 800–2 605 340)
	Public health	153	46%	308 076 978	37·8%	2 013 575 (4 053 184)	666 164 (375 387–2 209 865)
	Cross-disciplinary	65	20%	143 510 172	17·6%	2 207 849 (2 630 770)	1 071 300 (552 164–2 517 231)
Total		333	NA	814 381 928	NA	2 445 591 (4 054 664)	941 808 (419 529–2 605 340)

NA=not applicable.

^*Data are mean (SD).

^†Data are median (IQR).